EGFR and non-small cell lung carcinoma: The ctDNA analysis of T790M-mutant NSCLC patients, resistant to first line EGFR Tyrosine Kinase Inhibitor (TKI) therapy, revealed different patterns of genetic alterations in patients with innate versus acquired resistance to Osimertinib (Kato et al., 2021).